What are you searching for?

Press Release

4 Min read

Global Male Hypogonadism Market is was Valued at US$ 3.5 Bn in 2021 Growing at a CAGR of 5.7% Over the Forecast Period (2022 – 2030): A Report by Absolute Markets Insights

Published On 30 Jun 2022 11:58 AM


Male hypogonadism is a condition in which the body does not produce enough testosterone, an important hormone for male growth and development throughout puberty, or enough sperm, or both. Hypogonadism in men is more common as they get older. After the age of 40, men's testosterone levels begin to drop. The prevalence of testosterone insufficiency in men aged 50 to 79 years is estimated to be 8.4%. Male hypogonadism has also been connected to type 2 diabetes, with low testosterone levels being found in roughly 17% of men with the disease. The rising population of men with problems such as overweight and type 2 diabetes mellitus have both been identified as probable factors for the rising prevalence of male hypogonadism. According to this research, up to one-third of men with type 2 diabetes and a BMI of more than 30 kg/m2 have hypogonadism, which is defined by a low serum-free testosterone level. The reason for these patients' lower androgen levels is unknown; nevertheless, numerous theories have been presented to explain this phenomenon. Thus with rising male population suffering from hypogonadism, leading players in the market are introducing various medicines as well as treatments which in turn has led to the growth of the global male hypogonadism market.

During the Covid19 it was been studied that despite the fact that men and women have identical COVID-19 (SARS CoV-2) infection rates, male patients had twice the fatality rate in later age groups. According to research from China, Germany, and Italy, acute infection is associated with severe primary hypogonadism, and the lower the testosterone level, the higher the mortality rate. Some age-related conditions use hypogonadism, especially type 2 diabetes (T2DM), obesity, chronic heart disease (CHD), congestive heart failure, CKD, COPD, HIV, and long-term achen drugs. It is related to the rate of increase in men. Within these groups, secondary hypogonadism has been shown to be associated with increased mortality from all causes.

Get PDF sample report with all related graphs & charts (pre and post covid-19 impact analysis): https://www.absolutemarketsinsights.com/request_sample.php?id=1194

Segmental Analysis - Global Male Hypogonadism Market

Primary and secondary hypogonadism are the two kinds of classical male hypogonadism. When a low level of testosterone is caused by disorders affecting the testes, it is called primary hypogonadism. Hypergonadotrophic hypogonadism is a type of primary hypogonadism in which the pituitary gland produces too much luteinising hormone (LH) and follicle stimulating hormone (FSH) (gonadotrophins) in an attempt to stimulate the testes to make more testosterone. However, because the testes are damaged or absent, they are unable to respond to higher amounts of gonadotrophins, resulting in little or no testosterone production. Although testosterone levels may be normal in some patients with primary hypogonadism, elevated LH and FSH suggest that the pituitary gland is attempting to compensate for a shortage, and treatment may still be required. Low testosterone levels are caused by an underlying medical illness such as Klinefelter's syndrome, Kallmann's syndrome, or a pituitary tumor in classic hypogonadism. The drop in testosterone levels known as late-onset hypogonadism is associated to general ageing and/or age-related illnesses, including obesity and type 2 diabetes. Late-onset hypogonadism affects only approximately 2% of males over the age of 40, according to estimates. Thus, these factors are propelling the global male hypogonadism market.

Speak to our analyst in case of queries before buying this report: https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=1194

By therapy, testosterone replacement therapy and gonadotropin-releasing hormones therapy are the two therapies for male hypogonadism. Male hypogonadism (low testosterone or "Low T") is a condition in which the body fails to produce enough hormones due to a problem with the testicles, pituitary gland, or both. Testosterone levels in men begin to rise during adolescence and fall by 1% every year after the age of 30. In older men, a lack of this important sex hormone can lead to physical problems such as osteoporosis, loss of muscular mass and strength (sarcopenia), and psychiatric disorders. Only males with low testosterone levels due to illnesses that cause hypogonadism were approved by the FDA for testosterone replacement therapy. The government has stated, however, that testosterone is commonly used to help men with low testosterone symptoms. Testosterone is available in the form of a skin patch, skin gel, pill, or cream, as well as an injection, an armpit solution, and a patch or buccal system applied to the upper mouth or inner cheek. While many testosterone supplements require a prescription, certain drug stores and health food stores sell them over the counter. Moreover, there is a rise in awareness amongst a huge male population about the various products for male hypogonadism. Gels and patches are becoming quite popular due to its reduced side effects along with better results. On the other hand, injections have been in the market since a very long time. Depo-testosterone, for example, is one of the oldest drugs in the market, having been approved in 1979. It's a liquid that's meant to be inserted into the gluteal muscle. Thus, various products to treat male hypogonadism has led to the growth of the global male hypogonadism market.

View our exclusive press releases on Industry Global News24

Asia Pacific is anticipated to be the fastest growing region in the male hypogonadism market. In the Asia-Pacific region, an increasing prevalence of hypogonadism and infertility and an increasing elderly population with diabetes and obesity are driving the growth of this market. China, Taiwan and Malaysia are some of the countries with the highest incidence of hypogonadism in men. Furthermore Asia-Pacific region may offer favorable opportunities for this market due to the modernization of medical infrastructure in emerging countries like India and China and the growing awareness of treatments for this disease.

Competitors- Global Male Hypogonadism Market:

  • AbbVie
  • Antares Pharma, Inc.
  • Aytu BioScience, Inc.
  • Clarus Therapeutics, Inc.
  • Eli Lilly and Company
  • Endo Pharmaceuticals
  • Merck & Co. Inc.
  • Pharmacia & Upjohn Co. (Pfizer Inc.)
  • Teva Pharmaceutical Industries Ltd
  • Upsher-Smith Laboratories, LLC.
  • Other Market Participants

Purchase the latest in-depth Male Hypogonadism Market report: https://www.absolutemarketsinsights.com/checkout?id=1194

Global Male Hypogonadism Market:

By Type

  • Primary
    • Klinefelter syndrome
    • Mumps orchitis
    • Hemochromatosis
    • Others
  • Secondary
    • Kallmann's syndrome
    • Pituitary disorders
    • Inflammatory Diseases
    • Others

By Therapy

  • Testosterone replacement therapy
    • Topical Gel
    • Injections
    • Implantable pellets.
    • Transdermal Patches
    • Others
  • Gonadotropin-releasing hormones therapy

By Diagnosis

  • Hormone testing
  • Semen analysis
  • Pituitary imaging
  • Genetic studies
  • Testicular biopsy

By Region

  • North America (U.S., Canada, Mexico, Rest of North America)
  • Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
  • Latin America (Brazil, Argentina, Rest of Latin America)

Browse more trending reports by Absolute Markets Insights 

Sperm Separation Systems Market -


Global In-Vitro Fertilization Market -


Predictive Genetic Testing and Consumer Genomics Market - https://www.absolutemarketsinsights.com/reports/Global-Predictive-Genetic-Testing-and-Consumer-Genomics-Market-2022-%E2%80%93-2030-1158

DNA-Encoded Libraries Platforms And Services Market - https://www.absolutemarketsinsights.com/reports/DNA-Encoded-Libraries-Platforms-and-Services-Market-2021---2029-861

Glance through Absolute Markets Insights plethora of reports on Healthcare Category

About Us:

Absolute Markets Insights assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization. From the in-depth analysis and segregation, we serve our clients to fulfill their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.

Contact Us:

Contact Name: Shreyas Tanna

Company: Absolute Markets Insights

Email Id: [email protected]

Phone: IN +91-7400-24-24-24, US +1-510-420-1213

Website: www.absolutemarketsinsights.com


Press Release Provided By: Absolute Markets Insights